Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Degenerative neurological disorders

Alzheimer’s treatment explored as potential Down’s syndrome therapy

Phase II study finds Alzheimer’s disease-modifying drug is safe for patients with Down’s syndrome, but concludes more research is needed to test effects on cognitive function.

Cognitive impairment in Down’s syndrome shares some features with Alzheimer’s disease (AD), including overproduction of amyloid-beta and high levels of myo-inositol in the brain. People with Down’s syndrome are also at increased risk of developing AD.

In a phase II placebo-controlled study, researchers explored the safety and pharmacokinetics of a candidate disease-modifying therapy for AD, ELND005, in 23 young adults with Down’s syndrome. Participants received 250mg of ELND005 either once or twice daily, or placebo.

After four weeks, there were no adverse events attributed to the study drug and no serious adverse events. There were also no remarkable changes to laboratory findings, vital signs, electrocardiogram results or other physical findings.

The authors, reporting in the Journal of Alzheimer’s Disease[1] (online, 11 May 2017), say the results show the treatment is well tolerated, but the study wasn’t long enough or powered to detect efficacy. Future studies should examine its effects on cognitive and behavioural measures, they conclude.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2017.20203055

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £37.00Buy now
  • Drugs in Use

    Drugs in Use

    Optimise drug therapy for your patients. These case studies help you bridge the gap between theoretical medicines knowledge and practical applications.

    £42.00Buy now
  • Workplace Drug Testing

    Workplace Drug Testing

    Explains drug testing regulatory frameworks and all aspects of drug analysis. Case studies of successful programmes are included.

    £79.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £37.00Buy now
  • Minor Illness or Major Disease

    Minor Illness or Major Disease

    This established textbook helps you differentiate between minor illnesses which can be safely managed in the pharmacy, and major diseases.

    £42.00Buy now
  • Basic Pharmacokinetics

    Basic Pharmacokinetics

    A clear and concise basic pharmacokinetics textbook. Shows how to apply the principles to achieve successful drug therapy.

    £52.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Young man with Down's syndrome

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.